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Abstract
Surgery as resection or transplantation remains a fundamental means for cancer treatment and often offers an 
opportunity for a cure. However, surgery is not always possible because of tumor proximity to blood vessels or ducts 
or when a patient is not healthy enough to undergo surgery. Application of nanosecond pulsed electric fields (nsPEFs) 
is a new approach to treat cancer using pulse power technology that was originally designed for military purposes. 
This novel approach deposits extremely short pulses of high power, low energy electric fields into malignant tissues 
using electrodes to encompass tumors. Pre-clinical studies show that treatments are effective and without local or 
systemic side effects, including absences of scarring. Pre-clinical trials for basal cell carcinoma are completed, but 
results have not been published. For treating internal tumors, electric fields can be delivered by catheter electrodes 
and laparoscopy procedures. Here we present a review of the literature using nsPEFs for cancer ablation and present 
some recent work from the author’s laboratory. We demonstrate efficacy for treatment of an ectopic mouse (Hepa-1-
6) and an orthotopic rat (N1-S1) Hepatocellular Carcinoma (HCC). NsPEFs eliminate tumors by mechanisms in the 
presence of active caspases (apoptosis) as well as in absences of active caspases (necrosis/necroptosis). Treatment 
also breaches small vessels, but spares larger vessels and ducts. NsPEF treatments also reduce angiogenesis as 
determined by decreases in Vascular Endothelia Growth Factor (VEGF). Microvascular density markers (CD-31, 
CD-34 and CD-105) are significantly decreased after treatment, limiting new blood vessel formation and reinforcing 
tumor cell demise. Furthermore, initial challenge studies show that mice are resistant to re-introduction of the same 
tumor cells after treatment, suggesting that nsPEFs induces immunogenic cell death and possible host cell immune 
responses after treatment. NsPEF ablation of cancer targets at least three hallmarks of cancer (evasion of apoptosis, 
angiogenesis maintenance and immune surveillance) and provides an effective alternative or adjunct therapy for 
cancers in skin and internal organs. 
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Introduction
Brief highlights in the history of surgery
Perhaps the earliest evidence of surgery came from burial sites 
in France (6,500 BC) where indications of trepanation or drilling 
a hole in the skull were found [1]. These surgeons were nameless, 
but Urlugaledin (4,000 BC) was known as a surgeon in a cradle of 
civilization in the Tigris - Euphrates river valley in Mesopotamia [2]. 
Other early noteworthy surgeons included Imhotep (circa 2650–2600 
BC), an Egyptian scholar who was perhaps the first physician in early 
history and was considered the Egyptian god of medicine [3] and the 
god of science and thought [4]. He authored a medical treatise that 
excluded magic from medicine and contained anatomical observations, 
ailments, treatments and cures [5]. Sushruta (1000-600 BC), who was 
known as the “father of surgery”, practiced in Northern India around 
600 BC [2]. He authored the oldest known text in surgery, which 
included details of examinations, diagnoses, treatments, and prognoses 
of numerous ailments in addition to procedures on cosmetic surgery, 
plastic surgery and rhinoplasty [6]. The ancient Greeks, Herophilos 
and Erasistratus (~300 BC), were the first scientists to systematically 
dissect human cadavers. They founded the School of Anatomy in 
Alexandria from which came descriptions of ligature (hemostasis), 
lithotomy, hernia operations, ophthalmic surgery, plastic surgery, 
methods of reduction of dislocations and fractures, tracheotomy, and 
mandrake as anesthesia [7,8]. Hua Tuo (c. 140–208) [9], an ancient 
Chinese physician, was the first person to perform surgery with the 
aid of anesthesia (mafeisan or “cannabis boil powder) about 1600 
years before Europeans. Hippocrates, the “father of western medicine 
“founded the Hippocratic School of Medicine, which revolutionized 
medicine by establishing it as a distinct discipline and profession [10]. 
He spent 20 years in prison for differentiating medicine from religious 
beliefs, arguing that disease resulted from environmental factors, diet 
and living habits instead of punishment from gods [11]. Galen (c. 
129-200) [12], another Greek, who lived in the Roman era, was a very 
accomplished surgeon and physician who carried out very complex 
surgical operations and added significantly to our understanding of 
surgery as well as animal and human physiology. Throughout history, 
surgery made regular advances in times of war. Modern surgery did 
not begin until three major problems were resolved. These were pain, 
bleeding and sepsis. Anesthetics such as ether (1500s), nitrous oxide 
(early 1800s) and ether-chloroform (1840s) contributed significantly 
to the pain problem. Louis Pasteur (1822-1895) advanced the idea that 
bacteria caused infections; however, this idea was slow to be accepted. 
Lister (1827-1912) controlled infection using antiseptic surgery. This 
was followed by sterilization, use of rubber gloves and antibiotics, all 
contributing to the problem of infections. Before the bleeding problem 
could be settled, physicians had to realize that loss of blood was a major 
problem for survival. Bleeding patients was common practice for 
almost every ailment for hundreds of years. When physicians finally 
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realized hemostasis was critical for survival, bleeding was controlled by 
point pressure, tourniquets, cauterizations and ligatures. Replacing lost 
blood was addressed by transfusions, but understanding concepts of 
blood groups was required before transfusions were successful. There 
are a number of claims to the first “modern” surgery. Pertinent to this 
review, the Mayo brothers and father, who founded the Mayo Clinic 
(1914), conducted one of the first surgeries in the US by removing a 
cancerous growth from a patient at St. Mary’s Hospital (1905). Other 
significant advance is surgery came with the first successful kidney 
transplant (1954) at Peter Bent Brigham Hospital in Boston, MA 
[13] and the first successful heart transplant (1967) at Cape Town 
South Africa [14]. Other highlights in chronicles of surgery include 
the invention of the fiber optic endoscope (1963-64), laparoscopic 
or minimally invasive surgery and more recently, robotic surgery, 
including one or the earliest placing a needle for a brain biopsy (1985) 
[15] and prostate surgery (1988) [16]. Today robotics can be used in 
essentially all aspects of general surgery. 
Materials and Methods
Alternative therapies for treatment of cancer
At the other end of these developments is the replacement of surgery 
or inclusion of other treatments as adjuncts to surgery for treatment of 
cancers. For the purposes here, an overview of the earliest examples 
of nsPEF treatment of cancer and then a focus on Hepato Cellular 
Carcinoma (HCC) with an ectopic mouse model and an orthotopic 
rat model. For treatment of HCC, there are a number of alternative 
treatments to surgery with several relatively new technologies [17,18] 
using thermal approaches [radiofrequencies (RFA), microwaves 
(MWA), cryoablation] chemical-techniques (percutaneous ethanol/
acetic acid), radiological methods (transarterial chemoembolization 
and radioembolization, also RFA), High Frequency Ultrasound 
(HIFU) treatment. Importantly, there have been a number of non-
thermal methods used as alternatives to surgery and many of them use 
local electric fields as a means of treatment. More than a quarter of 
a century ago, it was shown that non-thermal applications of electric 
fields could alter plasma membranes of cells to transport DNA across 
their membranes. The authors proposed that electric field interaction 
with lipid dipoles at local defects in the plasma membrane could cause 
disordered structures, leading to permeation sites for DNA entry [19]. 
Electro gene therapy, or gene delivery to cells or tissues, is now being 
used in clinical trials and has been shown to be clinically safe and effective 
for deliveryIL-12 to melanoma patients [20]. Another non-thermal use 
of electric fields came into practice in a similar way to that used for gene 
transfer. Instead, electroporation was used to deliver chemotherapeutic 
drugs such as bleomycin that were impermeable to plasma membranes 
[21]. This is now commonly practiced in Europe for treatment of 
cancer [22]. Another non-thermal approach for treating cancer is to 
increase electric fields such that electroporation is irreversible, thereby 
eliminating tumor cells by Irreversible Electroporation (IRE) of plasma 
membranes [23,24]. At about the same time, nanosecond pulsed 
electric field (nsPEF) ablation was being explored in vitro and in vivo 
and is the major interest in this review.
Nanosecond pulsed electric field (nsPEF) ablation as a cancer 
treatment
Applications of nsPEFs have been used to eliminate several tumor 
cell types in vitro and tumor tissues in vivo. This approach uses pulse 
power technology that was originally designed for military applications. 
It stores intense levels of electric energy and then unleashes nanosecond 
bursts of instantaneous power into cells or tissues. This is believed to 
be significant because it creates unique intracellular conditions of high 
power and low energy. Because the pulses are so short, when using low 
pulse repetition rates, the method is essentially non-thermal [25,26]. 
However, when repetition rates are higher, some heat is generated. 
However, if temperatures do not increase to more than 40-42°C, the 
treatment can still be considered non-thermal. For example, in the 
first study treating B16f10 melanoma tumor in vivo, the temperature 
in the treated tumor rose from 28° to 31°C, clearly non-thermal [26]. 
In addition, ablation zones are very clearly defined based on electrode 
placements [27]. This allows precise treatment of tumors with 
appropriate margins of adjacent tissue, thereby minimizing damage 
to non-tumor tissue. Although there is some cell type specificity 
with nsPEFs [28,29], all cells surrounded by electrodes and exposed 
to sufficiently high electric fields should be affected and undergo 
cell death. Not only will cancer cells be affected, but other cells will 
be affected including host cells that support tumor growth and slow 
growing cancer stem cells that are not affected by agents that target 
rapidly proliferating cell, will be affected. NsPEF ablation induces 
caspase-dependent and caspase-independent programmed cell death 
[30], at least in part, by inducing supra-electroporation [31,32], which 
consists of high density nanopores, not only in plasma membranes 
but also in organelle membranes and possibly other mechanisms 
such as effects on voltage gated channels [33] and perhaps on proteins 
[34,35]. The effect on intracellular membranes is significant because 
permeabilization of plasma membranes is not always sufficient for 
cell death induction under nsPEF conditions [35]. While poration 
of plasma membranes and intracellular stores is critical for elevating 
intracellular calcium, effects on mitochondria membranes and/or 
channels and the mitochondria membrane potential (ΔΨm) appear 
to be required for nsPEF-induced cell death, at least under certain 
conditions [35]. Thus, by targeting plasma membranes, ΔΨm, and/or 
membranes surrounding intracellular calcium stores, applications of 
nsPEFs affect multiple therapeutic targets and cancer hallmarks [36]. 
Treating ectopic mouse B10.2 fibrosarcomatumors with 
nsPEFs
The first application of nsPEFs for cancer treatment was using 
B10.2 fibrosarcoma cells in vitro and in a mouse tumor xenograft 
model [37]. One of the major points was showing that nsPEFs differed 
from conventional electroporation. In so doing, in vitro studies 
exposing cells to nsPEFs in cuvettes demonstrated that nsPEFs induced 
apoptosis markers including the presence of active caspases and 
phosphatidylserine externalization, which was most likely due to direct 
electric field effects on plasma membranes [38]. In tissues removed 
from ectopic tumors and treated ex vivo in cuvettes, a 6-fold increase in 
TUNEL positive cells was observed compared to sham treated controls 
5 hours after treatment with nsPEFs. Mouse B10.2 tumors were 
also treated in vivo. These treatments primarily served as a proof of 
principle that nsPEFs could have a deleterious effect on tumors. Tumor 
cells were implanted in each flank of mice. One tumor served as a sham 
control and the contra lateral tumor was treated. Since these were the 
first in vivo studies carried out with nsPEFs, there were no guidelines 
to choose treatment conditions. After tumors reached about 5-8 mm 
in diameter as measured by calipers (day 0), tumors were exposed to 
two pulses with durations of 300 ns and electric fields at 75 kV/cm and 
1 Hz on day 2 and 5 pulses under the same conditions on day 5using 
a two needle electrode. In 5 animals, treated tumors grew 62% slower 
than sham controls. In three other animals, treated tumors were 60% 
smaller by weight than sham controls. It is now known that these 
treatment conditions were far less rigorous than needed for tumor 
elimination based on results from treatment of ectopic mouse B16f10 
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melanoma, ectopic mouse Hepa1-6 HCC and orthotopic rat N1-
S1 tumors (see below). Nevertheless, these experiments verified that 
nsPEFs could induce apoptosis in vitro and ex vivo and significantly 
reduce tumor growth in vivo. In studies that followed with Jurkat cells 
in vitro, it was shown that nsPEFs induced cytochrome c release and 
activated caspase-3 catalytic activity, confirming that apoptosis was at 
least one of the cell death pathways induced by nsPEFs [39]. A later 
paper demonstrated the presence of caspase-dependent as well as 
caspase-independent activities in Jurkat cells [30].
Treating mouse B16f10 melanoma tumors in vivo with 
nsPEFs 
Later, nsPEFs were shown to eliminate mouse B16f10 tumor in a 
mouse ectopic model without recurrence under optimal conditions 
[26]. In these studies two different delivery electrode designs were 
tested including a 5 needle array and two parallel plates. When the 5 
needle array was used, the electric fields were heterogeneous with the 
highest field at the center needle and field lines parallel to the surface of 
the skin. Treated tumors shrink by about 75% within 8 days when given 
two treatments with 100 pulses with durations of 300 ns and electric 
fields at 20 kV/cm and 0.5 Hz. Tumor responses were dependent 
on electric fields and pulse numbers. After pulsing, blood flow to 
tumors was interrupted and did not recover for about two weeks. 
In addition to tumor damage, the stratum corneum was damaged, 
showing signs of necrosis and hemorrhage. Interestingly, this was not 
a thermal injury or a burn, which would be expressed immediately; the 
temperature increase was only 3°C, significantly lower than required 
for a hyperthermic injury. Thus, this is more likely an electrical injury, 
perhaps due to effects on proteins caused by dissociation of ionizable 
side groups, reorientation of peptide dipoles within the protein in the 
direction of the electric field, conformational changes and denaturation 
[40]. Using the plate electrode design, tumors were positioned between 
parallel plates. This provided a more homogeneous electric field, which 
was oriented perpendicular to the skin surface instead of parallel to it, 
like that with needle electrodes. In this configuration, the surface of 
the skin was between electrodes and the tumor. Using four 100 pulse 
treatments (3 on day 0 and 1 on day 3) and electric fields of 40 kV/cm, 
tumors shrank by 90% in two weeks. The skin responded with a black 
scab on the stratum corneum, composed of clotted red blood cells, 
which remained for about two weeks during regeneration of the stratum 
corneum. After about two weeks of regression, all tumors began to grow 
again. When tumors began to grow again and were given additional 
treatments including a 3 day series of 100 pulses, a complete remission 
was observed for as long as two months. Two immediate changes after 
nsPEF treatment were hypothesized to cause tumor regression. One 
was a rapid pyknosis of tumor nuclei and the other a cession of blood 
flow to tumors. Within the first few minutes, tumor cell nuclei shrank 
by 54% and within 3hours they shrank by 68%. The absence of blood 
flow to tumors within the first 15 minutes after treatment was indicated 
by trans-illumination and power Doppler ultrasound reconstructions. 
As long as blood flow did not return to treatment areas, tumors did 
not return; however, if blood flow returned with two weeks after 
treatment, tumor growth returned. In addition to killing tumor cells, 
as indicated by pyknotic tumor cell nuclei, the absence of blood flow 
appears to be an important factor to tumor regression. In later studies, 
it was shown that B16f10-eGFP tumors could be eliminated in a single 
treatment using 2000 pulse with duration of 100 ns at 30 kV/cm at 5-7 
Hz [41]. These studies differ from the previous one in several ways. This 
study used Nu/Nu mice, which are immunodeficient, instead of SKH-
1 mice, which have a relative strong immune system. The treatments 
were with shorter pulse durations (100 ns instead of 300 ns) and higher 
repetition rates (5-7 Hz instead of 0.5 Hz). The higher repetition rate 
caused temperatures to increase to about 40°C, yet the treatment 
is still considered non-thermal. Another difference included using 
suction electrodes, which were compatible for human use. This design 
limited the treatment volume to tissues that could be placed between 
electrodes within the suction cup. The skin was also affected by this 
nsPEF treatment; however, scabs that formed fell off by the end of the 
second week, leaving a coloration difference from untreated skin that 
faded leaving no scar. In unpublished clinical trials, nsPEFs affected 
human skin causing only mild irritation, erythema and itching leaving 
some discoloration that faded and no scar [42]. Thus, an important 
advantage and benefit for nsPEF treatment of skin cancer over surgery 
is the absence of scarring after treatment. Effective ablation was 
achieved in radiation-induced murine Basal Cell Carcinomas (BCC), 
which was similar to human BCC, in Ptch1+/-K14-Cre-ERp53fl/fl mice 
using a 6-post dual configuration suction electrode, which was the 
best of three electrode designs tested. The electrode configuration and 
complete encapsulation of the tumors were critical components for 
complete ablation in a single treatment. Using 2700 pulses with 100 ns 
durations and electric fields of 30 kV/cm at 5-7 Hz, BCC tumors shrank 
76% at 2 weeks and 99.9% at four weeks after treatment [43]. Complete 
ablation without recurrence of human pancreatic carcinoma was also 
demonstrated in a murine xenograft model using similar conditions, 
but with 500-1000 pulses showing good efficacy [44].
The devastation of Hepatocellular Carcinoma
Liver cancer is the third most common cause of mortality 
worldwide [WHO statistics] and Hepato Cellular Carcinoma (HCC) 
is the most common, occurring in 75% of all liver cancers [45]. Africa 
and Southeast Asia have highest incidences of HCC and it is the most 
common cancer in Japan. The incidence and mortality rates of HCC 
are nearly equal because the fatality rates are so high. The prognosis for 
HCC is usually poor because symptoms and diagnosis do not generally 
occur until advanced stages. The incidence and mortality rates have 
increased recently in the US and are affecting younger persons, mostly 
due to increased infections with hepatitis C and B viruses [46]. While 
the prognosis of cancer patients is generally determined by tumor size, 
HCC treatment efficacy is also determined by underlying diseases 
such as cirrhosis or other functional maladies [47]. These underlying 
diseases, in part, account for poor responses to chemotherapeutic 
agents and ionizing radiation and also account for <20% of patient 
eligibility for resection. Still, several new developments have led to 
increases in early diagnoses including greater awareness of the disease, 
new screening approaches and more definitive diagnosis using high-
resolution imaging of the liver [48]. Yet, a major remaining barrier is 
the absence of successful management strategies that avoid multiple 
treatments and prevent recurrences. One of the most comprehensive 
classification system used for HCC in the US is the Barcelona-Clinic 
Liver Cancer (BCLC) staging classification and treatment schedule 
[49,50]. The system includes 5 tumor staging categories that consider 
size and number of nodules, the degree of liver function and the 
presence or absence of metastasis. They include very early (O), early 
(A), intermediate (B), advanced (C) and terminal (D) stages. Stages O, 
A and B are treated with resection, liver transplantation, percutaneous 
ethanol (or acetic acid), radiofrequency ablation or Transcatheter 
Arterial Chemoembolization (TACE). Advanced and terminal stages 
are generally treated with palliative measures. HCCs are generally 
resistant to chemotherapeutic agents and radiation. For example, 
sorafenib is a new oral multi-kinase inhibitor for advanced HCC 
with modest clinical efficacy extending survival by only a few months 
[51,52]. New treatment strategies are needed for stages O, A and B 
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that avoid multiple procedures and recurrences. This is a niche that 
can be filled using pulse power technology with nanosecond pulsed 
electric field (nsPEF) ablation of HCCs. Hepatocytes are the major 
liver cell type and are vulnerable to most forms of liver injury either as 
primary or secondary insults. Continuous cell turnover by apoptosis, 
which is tightly coupled to inflammation and fibrosis [53-55], leads to 
activation of myofibroblasts, hepatic fibrosis, cirrhosis and HCC [56]. 
Such chronic pro-apoptotic pressure provides the basis for cancer-
related mutations and promotes development of apoptosis evasion 
[57], a hallmark of cancer [36]. Production of pro-inflammatory 
products from macrophages, stellate cells and Kupffer cells during 
phagocytosis of apoptotic bodies appears to be responsible for the link 
between apoptosis and fibrosis [53,57,58], a paradigm that appears 
to be unique to hepatocyte apoptosis. Cancer also emerges when 
immunological control fails and transformed cells develop resistance 
against cell death signaling pathways. The same mechanisms underlie 
the poor responsiveness of HCC towards chemotherapy. Mechanisms 
of cell death exhibit complexity beyond apoptosis and necrosis as 
cross-talk among signaling pathways involved in cancer hallmarks 
makes clear. Also the tumor microenvironment has an impact on cell 
signaling and cell death. While significant progress has been made in 
understanding tumorigenesis and cancer molecular biology, the overall 
therapeutic effects on cancer mortality have been disappointing. While 
the primary pathways that drive cancer are known and a significant 
number of drugs targeted for these pathways have been developed and 
tested, virtually none of these drugs or treatments has provided a cure. 
The scientific community is conceptually reexamining approaches 
for cancer treatment, considering cancer as manifestations of eight 
essential hallmarks [36] and instead of conceiving cancer as a foreign 
invader [59], reevaluating cancer as a criminal gang (the cancer) within 
the local community (cancer microenvironment) that coerces the local 
population (supporting host cells, blood vessels) to use their resources 
(growth, differentiation and vessel-forming factors) to support the 
gang’s criminal activity (the tumor as an organ). 
Treating ectopic mouse Hepa1-6 HCC tumors in vivo with 
nsPEFs
As a first step to address the possibility of using nsPEFs for treating 
HCC, an ectopic mouse Hep1-6 HCC tumor model was established in 
C57BL/6 mice and optimal conditions were determined as well as cell 
death mechanisms in response to nsPEF [60]. In this study a number 
of different conditions were tested. Pulses with durations of 30 or 100 
ns and fast rise times were delivered by an electrode with a5 needle, 
4 + 1 configuration or an electrode with a center needle and a solid 
ring surrounding it. The electric field distribution in both electrode 
configurations were heterogeneous with electric fields as high a 230 
kV/cm at the center needle with electric fields decreasing towards the 
ground electrodes, where electric fields were on the order of 40-90 kV/
cm [60]. Different electric field strengths (33, 50 and 68 kV/cm) were 
tested with 900 pulses delivered at 1 Hz as a single treatment or as 3 
separate treatments on days 1, 3 and 5 with 300 pulses each. The mice 
were followed for 269 days after treatment. For those mice that survived 
after treatment, this is a significant cancer free span considering this is 
approximately half of a mouse’s life expectancy. If this would translate 
to humans with an average life expectancy of 80 years and ignoring 
differences in cancer growth rates, which varies significantly among 
cancers, an individual who was diagnosed with cancer and successfully 
treated by the age of 40 could live cancer free of the rest of their life. This 
is significant since with optimal treatment conditions, 75% of treated 
animals survived this long when the experiment was terminated. In 
these studies, optimal treatments with 75% survival include 900 pulses 
either delivered at one time or 3 times with 300 pulses each on alternate 
days, with durations of 100 ns and electric fields at 65 kV/cm and 1 Hz. 
Generally, after tumors were treated, they stabilized or grew slightly 
larger until the third day when they decreased in size and were non-
detectable by 14-21 days. Control, sham treated tumors continued to 
grow for about 14-18 days when mice were humanely euthanized due 
to tumor burden. When pulse durations were decreased to 30 ns or 
electric fields were decreased to 33 or 50 kV/cm, treatment efficacies 
were significantly lower. For those tumors that were treated under 
optimal conditions, the tumor cell nuclei rapidly decreased in size 
during the first hour. Tumor cell nuclei featured highly condensed 
chromatin, segregating into sharply defined bodies (nuclear pyknosis) 
by 3-6 hours after treatment. Fifty to sixty percent of treated tumor 
nuclei were TUNEL positive by 3 hours after treatment. The number 
of TUNEL positive cells decreased thereafter over the next 12-24 
hours. The presence of active executioner caspases, as identified by 
specific antibodies, followed a similar time course after treatment. The 
presence of active caspase-3, -6 and -7 peaked at 3 hours and decreased 
thereafter over the next 5 hours. Active caspase-3, -6 and -7 activity 
was present in about 45-50%, 12-18% and 20-40% of cells, respectively, 
3 hours after treatment at their peak. Activities of capase-3 and -6 fell 
off rapidly between 4-8 hours after treatment but caspase-7 activity fell 
at a slower rate. Since these analyses were carried our separately, it is 
not possible to know whether a given cell exhibited more than one or 
more than one active caspase or whether there were cell type specificity 
for specific caspases. Nevertheless, it is likely that not all cells exhibit 
active caspases and are undergoing caspase-independent cell death. 
Since after efficacious treatment all tumors disappear, there are few or 
no cells that do not undergo cell death. Another indicator of apoptosis 
was the absence of phosphorylated Bad in effectively treated Hep1-6 
tumors. When Bad is phosphorylated, it is bound to the protein 14-3-3, 
which removes it from possible heterodimerization with Bcl-xl or Bcl-
2, which neutralizes their protective effect on mitochondria thereby 
promoting survival [61]. When Bad is in the un-phosphorylated form, 
which was present in treated Hep1-6 tumor cells, it heterodimerizes 
with Bcl-xl or Bcl-2, thereby removing their protective effect promoting 
cell death. Therefore, the presence of active caspases and the absence 
of phosphorylated Bad are conditions that promote cell death by 
apoptosis. It was previously shown that nsPEFs had significant effects 
on tumor vascularity in B16f10 melanoma tumors in vivo [62]. In these 
studies, it was shown that there were progressive decreases during 
21 days after treatment in Vascular Endothelial Cell Factor (VEGF), 
the most ubiquitous pro-angiogenic factor, a requirement for the 
angiogenic switch [63], a limiting factor for multistage carcinogenesis 
[36] and Platelet Derived Endothelial Growth Factor (PD-ECGF). In 
addition there were progressive decreases over this same time period 
for several micro vascular density factors, including CD-31, CD-34 
and CD-105. CD-31 (PECAM-1), a platelet-endothelial cell adhesion 
molecule used as a pan-endothelial cell marker, and CD-34, an 
endothelial cell marker, were decreased by 65-70%. CD-105 (endoglin) 
was decreased >40%. CD-105, which is part of the TGFβ receptor 
complex, is an important angiogenic factor that is strongly expressed in 
tumors and is an independent prognostic indicator, wherein increased 
MVD correlates with shorter survival [64].
Does nsPEF treatment induce an immune response in ectopic 
mouse Hep1-6 HCC tumors?
Using this same mouse Hep1-6 model in C57BL6 mice, we decided 
to challenge mice with a second injection in the opposite flank of the 
same Hep1-6 tumors cells after the primary tumor had been successfully 
cleared for 60 days [65]. Age match, naïve control mice were also 
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injected in the same way. When Hepa 1-6 tumors were successfully 
clear after treatment with treatments with 900 pulses at 100 ns and 55 
kV/cm in 6 of 8 treated mice, tumors cells were injected in the opposite 
flank as before. None of those 6 mice that were successfully treated 
before grew tumors for 49 days before the experiment was terminated. 
In naïve age-match control HCC tumors grew to treatable sizes in less 
than two weeks. These results suggest that nsPEF ablation allows a host 
cell immune response. While these studies must be repeated and the 
mechanisms of this resistance further investigated, these results suggest 
that nsPEF ablation addresses another cancer hallmark, evasion of 
immune surveillance. Another study compared treatments with 
nsPEFs and surgical removal of B16f10-GFP in melanoma in SKH-1 
mice [66]. After the respective treatments, challenge injections if the 
same cells grew much slower in nsPEF-treated mice that those mice 
treated with surgery. In addition, CD4+ T-cells were present in treated 
tumors as well as tumors that had not been treated in mice with treated 
melanomas. These results suggest than nsPEF-stimulated tumor cell 
death induces an immune response. The results from the Hep1-6 in 
vivo studies indicated that nsPEFs act on several cancer hallmarks [36]. 
These include resisting cell death by apoptosis, resisting angiogenesis 
(or anti-vascular activities) [60,62] and perhaps overcoming evasion of 
immune surveillance [65,66].
Treating orthotopic rat N1-S1 HCC tumors in vivo with 
nsPEFs
In more recent studies, we have established and tested an orthotopic 
rat N1-S1 HCC using conditions similar to those in the Hep1-6 
mouse model discussed above. The studies carried out previously 
demonstrated that nsPEF could effectively eliminate tumors when they 
were implanted under the skin. We wanted to extend applications of 
nsPEFs to treating internal tumors. Given successes with the ectopic 
mouse HCC model and the “HCC problem”, which is increasing in the 
US and already a major problem worldwide, we pursued application 
of nsPEF to HCC tumors implanted in the liver of rats. We chose a 
rat model because of the larger liver and the need to carry out two 
surgeries and later three surgeries to demonstrate efficacy of nsPEFs. 
Thus, these studies combine nsPEF treatment with laparotomy as a 
proof or principle, before establishing treatments with laparoscopy and 
catheter electrodes. Thus, in this model, we introduced N1-S1-Luc cells 
under the liver capsule through a small incision in the abdominal wall. 
N1-S1 cells were stably transfected with a luciferase gene downstream 
of a CMV promoter. When tumors grew to about 0.5 cm, we exposed 
the liver again and treated with nsPEFs before closing. Tumor growth 
was monitored by luciferase activity (luminescence) ultrasound. In this 
model, we used a 5 needle (4+1) array [60] and treated tumors using 
pulses with electric fields at 50 kV/cm and delivered at 1 Hz and pulse 
durations of 100 ns with a rise-fall time of 10 ns. A study was carried 
out testing 100, 300, 500 or 1000 pulses. Fourteen days after treatment, 
rats were humanely euthanized and tumor sizes were determined. 
Analysis of HCC tumors by size and bioluminescence after 
nsPEF treatment
Figure 1 shows results indicating tumor sizes were decreased 
with all pulse numbers. Using 100 pulses tumor sizes were decreased 
but were only significantly less than sham-treated controls 14 days 
after treatment. Tumor sizes were smaller using 300, 500 and 1000 
pulses with the later condition decreasing tumor size about 6-fold. In 
subsequent experiments, when treated tumors were measured 6 weeks 
later, the 100 and 300 pulse conditions were insufficient to eliminate 
tumors; tumors had continued growing slowly between 2 and 6 weeks 
after treatment. We had initiated tumor development using an N1-S1 
clone stably transfected with luciferase to monitor tumor growth by 
luminescence. Figure 2 and table 1 shows tumor luminescent images 
of the same rats taken in the IVIS 100 in a sham-treated control and a 
rat treated with 1000 pulses with durations of 100 ns and electric fields 
at 50 kV/cm delivered at 1 Hz. Luminescent images were determined 
on the day of treatment (day 0) and 7 and 10 days after treatment. 
The table below the image indicates luminescence values and tumor 
sizes based on luminescence. Tumors from one sham-treated and one 
typical nsPEF- treated rat are shown as examples. It can be seen that by 
day 7 the sham treated tumor grew 5-6-fold compared to the size just 
before treatment and continued to grow for 10 days. In the treated rat, 
there was no detectable luminescence, indicating that treated tumors 
were absent 7-10 days after treatment. In order to evaluate longer 
term efficacy of nsPEFs, we treated tumors and evaluated the presence 
or absence of tumors seven weeks post-treatment. Figure 3 shows 
a Kaplan-Meier survival curve [67] for one experimental series with 
7 rats that were sham treated and 8 rats that were treated with 1000 
pulses with durations of 100 ns and electric fields at 50 kV/cm and 1 
Figure 1: N1-S1-Luc HCC tumor sizes 14 days post-nsPEFs treatment. – N1-
S1 cells were transfected with the gWiz-Luc plasmid driven by the CMV IE 
promoter (Aldevron, Madison WI). Clones were isolated as stable transfectant 
and the clone with the highest expression level was used. A liver lobe from 
Sprague Dawley rats (Harlan, Frederick MD) was exposed through a small 
incision in the abdomen and rat N1-S1-Luc HCC cells (1x106) (N1-S1 from 
ATCC) were injected under the liver capsule. Seven days later, the liver 
lobe was again exposed though an abdominal incision and tumors (~0.5 
cm in diameter) were treated with various pulse numbers with durations of 
100 ns, electric fields of 50 kV/cm at 1 Hz (n=8 for all groups). Rats were 
humanely euthanized 14 days after treatment. Treated lesions were excised 
to determine volume (A) and weight (B). Tumor volumes were determined 
using the formula for prolatespheroids (square of the width x length x 0.52): V 
= 0.52 x (D1 x D2) x2, where D1 and D2 are short and long tumor diameters, 
respectively. The symbols “*” indicates statistical significance compared with 
the zero pulse group. P values were calculated using a one-way ANOVA 
followed by Tukey tests (* p<0.05, ** p<0.01 ***p<0.001).
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Hz. The results show that the all sham-treated rats had to be humanely 
euthanized by 25 days after tumor initiation because of tumor burden 
(1.5-2.0 cm) according to our IACUC protocol. All 8 rats treated with 
nsPEFs remained alive and tumor-free for at least 49 days. When tumor 
size was checked after humane euthanasia or when rats were exposed 
to a second challenge injection of N1-S1 tumor cells, treated tumors 
were complete absent and liver tissue had returned to normal hepatic 
structure in the treated area.
Effect of nsPEF treatment on liver blood flow
It was previously demonstrated that nsPEFs had significant effects 
on blood flow in the areas of treated ectopic B16f10 [26,62] and Hepa1-
6 HCC tumors [60]. While this was advantageous to inhibit ectopic 
tumor growth, we were interested to evaluate post-treatment liver 
blood flow, which is heavily vascularized. Effects on liver blood flow are 
important in HCC treatment since it is common for HCC patients to 
have compromised liver function. Figure 4 shows blood flow analysis 
by laser Doppler before, immediately after and 7 days after treatment. 
Immediately after treatment, blood flow was decreased by 50-60% in 
the treated liver area. Only the treated area was affected. However, 7 
days later, blood flow had returned to normal and tended to be greater 
than the original control. This suggests that in nsPEF treated liver, 
effects on blood flow or anti-vascular effects or effects on angiogenesis, 
which occurred in ectopic tumors, is not likely to be a factor or a 
cancer hallmark in nsPEF treated HCC demise. Nevertheless, nsPEF 
treatments are an effective therapy for HCC.
Histological examination of normal liver and sham and HCC 
treated tissue
In order to determine effects of nsPEFs on treated N1-S1 HCC 
tumor tissue and compare it to normal liver and sham-treated control 
tumor tissue, we collected samples two weeks post-treatment from each 
of these tissues and prepared them for H&E staining and microscopy 
(Figure 5). The image of normal control liver shows a central vein and 
normal lobular hepatic architecture with cellular cords radiating from 
it with asymmetrical sinusoids and a typical scattering of collagen. In 
sham treated N1-S1, cancer cells can be seen infiltrating normal hepatic 
tissue with globular-like structures and sparse nuclei. Leukocyte 
infiltration in peripheral areas is evident. The vascular structures 
containing red cells are irregular and more numerous than in normal 
liver. In nsPEF-treated N1-S1 HCC, the cancerous tissues is completely 
destroyed with an absence of globular cancer cells and an enormous 
infiltration of leukocytes. We more-or-less expected this massive 
leukocyte infiltration given our previous results in Hepa1-6 HCC 
treated tumors. We had previously observed that after successfully 
treating Hepa1-6 HCC mouse tumors with nsPEFs (1000 pulses, 100 
Figure 2: NsPEFs eliminate N1-S1-Luc tumors determined by luminescence 
7-10 days after treatment. -Tumors were initiated as indicated in the legend 
to Figure 1. Seven days after initiation tumors were treated with 1000 pulses 
(1000X) with durations of 100 ns and electric fields at 50 kV/cm at 1 Hz. 
On the day of treatment (day 0) and 7 and 10 days after treatment tumor 
bioluminescence was determined on the same animals using non-invasive 
in vivo imaging with the IVIS Spectrum (Caliper Life Sciences, Xenogene). 
One sham-treated tumor and one typical rat with a treated tumor are shown. 
Days  post-treatment 
Sham 1000X
0            7           10 0            7            10
Days post-treatment 0 days 7 days 10 days
Sham Luminescence (p/s) 9.47×106 5.40×107 4.28×107+2.28×107
Area (cm2) 0.545 2.58 2.92+2.25
1000x 
nsPEFs
Luminescence (p/s) 1.54×107 0 0
Area (cm2) 0.957 0 0
Table 1: The table below indicates the luminescence units and tumor area in cm2. 
The designation 1000X indicates that tumors were pulsed 1000 times.
Figure 3: NsPEFs eliminate tumors for as long as 7 weeks. – N1-S1-Luc 
tumors were initiated and treated with 1000 pulses with 100 ns durations 
and 50 kV/cm at 1 Hz. In this typical trial, 7 sham and 8 treated rats were 
treated. After treatment, tumors were followed and analyzed by ultrasound. 
When sham treated tumors reach 1.5 cm, they were humanely euthanized 
according to our IACUC approved protocol. Forty nine days after treatment 
the experiment was terminated and animals were humanely euthanized. All 
surviving animals had been treated and were tumor free. The designation 
1000X indicates that tumors were pulsed 1000 times.
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ns, 55-60 kV/cm at 1 Hz) (6 out of 8 mice), challenge injections of 
the same tumor cells in the opposite flank 49 days later failed to grow 
tumors (6 out of 6 mice), while age-matched, naïve control mice readily 
grew tumors (6 out of 6 mice) [65]. These results are under continuing 
investigation to determine more specifically if an immune response is 
present in the orthotopic N1-S1 HCC model. 
Does nsPEF treatment induce an immune response in 
orthotopic rat N1-S1 HCC tumors?
In ongoing studies, rats with successfully treated tumors have 
been challenged with a second injection or a challenge injection of the 
same N1-S1 cells that initiated original tumors. In these preliminary 
studies the challenged tumors do not grow while naïve age-matched 
control rats grow tumors like those tumors in sham treated control 
rats. This suggests that, like response to challenge in ectopic Hepa1-6 
in mice, response are similar in rats, indicating that this phenomena 
is not species specific, is evident in an orthotopic HCC model and not 
confined to tumors originating in skin. The absence of challenge-tumor 
cell growth after successful nsPEF treatment of mouse Hepa1-6 and 
rat N1-S1 HCC tumors suggests the presence of immunogenic cell 
death. These results also indicate that these nsPEF-induced challenge 
phenomena are not species-specific. The mechanisms for immunogenic 
cell death are becoming clearer; however this clarity is complex. It is 
now known that physiological cell death, which is immunologically 
silent or tolerogenic, and cancer cell death, which can be immunogenic, 
are perceived differently by the immune system [68]. Thus, there must 
be mechanisms that differentiate among types of cell death [69]. Some 
(doxorubicin, cyclophosphamide, oxaliplatin) but not all apoptotic 
stimuli can induce immunogenic cell death, suggesting biochemical 
heterogeneity within apoptosis mechanisms. Those chemotherapeutic 
agents that do induce immunity depend on it for at least part of their 
efficacy [70,71]. There is also evidence that cells that experience stress 
responses and enter autophagy before undergoing apoptosis, necrosis 
or secondary necrosis may exhibit a more robust immunologic cell 
death. Induction of senescence by p53 in HCC can stimulate a robust 
anti-tumor response [69]. There are a number of factors that work 
together that determine whether cell death is immunogenic or not. 
These include the “history” of the cell, such as activation state or stress 
responses; the nature of the cell death stimulus; the cell death pathway 
and the availability of competent immune cells to carry out the response 
[69]. It appears that the pre-apoptotic exposure to calreticulin and the 
late apoptotic or secondary necrotic secretion of high mobility group 
box 1(HMGB1), which acts on the toll-like receptor-4 on dendritic cells, 
stimulates optimal antigen processing [68,72]. It will be interesting 
to determine whether nsPEFs exhibit some of the characteristics of 
immunogenic cell death. Such responses would provide significant 
advantage to prevent tumor recurrence and possibly vaccinate against 
HCC tumors that express the same antigen(s).
NsPEFs combined with other treatment modalities
NsPEF ablation impacts several well-characterized cancer 
therapeutic targets. It has shown success as a substitute for drug 
therapy and can be used in combination with other treatments; 
multiple therapies are common in essentially all cancer treatments 
and have been tried with nsPEFs [73]. In studies using concurrent 
treatments with low concentrations of gemcitabine and nsPEFs in 
mouse Cal 27 squamous cell carcinoma cells, synergistic activities 
were observed compared to summation of both treatment alone for 
inhibiting cell proliferation and inducing apoptosis and necrosis. The 
synergistic response was non-specific, or atleast not universal, since no 
synergism for cell invasion was observed with combined treatments. 
While these experiments were designed to reduce tumor burden with 
nsPEFs before chemotherapy, other strategies could include sensitizing 
tumors with a chemotherapeutic agent(s) before treating with nsPEFs 
or reducing tumor burden with nsPEFs before resection.
Summary of cancer treatment with nsPEFs
NsPEF ablation therapy has a number of advantages for anti-tumor 
effects. They have several therapeutic targets, which are included in a 
single treatment as opposed to treating cancer with individual agents 
that affect evasion of apoptosis, sustained angiogenesis (or anti-
vascular), and evasion of immune responses. The anti-vascular effect 
may be limited to tumors implanted or developed in the skin; however, 
additional studies of vascular effects in highly perfused liver warrant 
further investigation. The evasion of immune responses assumes the 
latter response is supported by further testing with nsPEFs in vivo. 
Certainly this last response will provide a substantial benefit for cancer 
treatment. Furthermore, nsPEFs induce cell death by caspase-dependent 
and –independent mechanisms [30] by targeting mitochondria and 
plasma membranes for calcium influx [35]. The heterogeneity of these 
effects is meaningful because nsPEFs can bypass a number of possible 
cancer mutations when tumor cells are adequately treated as shown 
here for treating N1-S1 HCC. For example, since nsPEFs can induce 
caspase-independent cell death, oncogenic mechanisms that evade 
apoptosis can be superseded. In contrast, the treatment itself is well 
defined by placement of electrodes to surround the tumor [27]. This 
stipulates specificity for tumor tissue and surrounding margins to 
minimize damage to surrounding non-cancerous tissues. When electric 
fields are sufficiently intense within this treatment zone, all cells can be 
killed, including tumor cells and host cells that provide needed growth 
and angiogenic factors for tumor growth, sustenance and metastasis. 
Given that nsPEFs can eliminate cells regardless of their proliferation 
rate, and in fact require less intense conditions (fewer pulses or lower 
electric fields) for cells that are not proliferating (are not in the S-phase) 
[74], it is likely that when electric fields are high enough, nsPEFs can 
also eliminate slowly dividing cancer stem cells, which could eliminate 
one possible cause of recurrences of disease, which can occur with 
agents that only affect rapidly proliferating cells. For treatment of skin 
tumors, nsPEF do not appear to leave scars after treatment in mice [26] 
or humans [42]. This will have valuable significance for individuals 
with skin cancer. Finally, there is an absence of local or systemic 
side effects with nsPEF treatment, providing an improvement over 
treatment with chemotherapeutic agents and ionizing radiation. When 
Figure 5: NsPEF treatment destroys HCC tumors and induces infiltration of 
immune cells. – N1-S1-Luc HCC tumors were initiated as described in the 
legend to Figure 1 and treated as described in the legend to Figure 2. Then, 
14 days after treatment rats were humanely euthanized and liver tissue was 
taken from normal liver removed from a distant untreated lobe, from sham-
treated HCC tumor and from HCC tumor treated with nsPEFs. Tissues were 
washed in PBS, fixed in 10% Neutral Buffered Formalin (NBF), followed by 
paraffin embedded, sectioning and H&E staining. Images were visualized 
using a Nikon Eclipse 50i microscope (Nikon, Tokyo, Japan) equipped with a 
10X/0.25 numerical aperture, and acquired using a Go-5 camera (QImaging, 
Surrey, Canada) and QCapture Pro 6.0 software.
Normal Liver Sham 1000 pulses
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these agents would be used in combination with nsPEFs, their doses 
can be significantly reduced into non-toxic ranges.
Future directions for treatment of cancer with nsPEFs
Nearly all studies with nsPEFs have been conducted in vitro with 
cells in culture or in vivo as preclinical investigations in mice and 
rats. In essentially all of these studies, which only a limited number 
are discussed here, nsPEF ablation has been highly effect against all 
tumor cells and tissues tested. The in vivo studies reviewed here suggest 
that clinical trials could most easily begin with skin cancers such as 
squamous cell carcinoma and/or basal cell carcinoma. This is supported 
by one example of an nsPEF-treated human basal cell carcinoma from a 
single patient who had a complete pathological response and the tumor 
was eliminated [75]. In fact, one human clinical trial treating basal cell 
carcinoma has been completed, but not yet published [76]. Of course, 
funding for these trials are difficult to secure and this is presently an 
issue with such low funding levels and financiers showing caution 
with investments. The other viable cancer for nsPEF ablation is cancer 
in internal organs such as HCC or pancreatic tumors. Before these 
studies begin, catheter electrodes must be developed for laparoscopy 
approaches which would avoid invasive surgeries. Finally, confirming 
and defining molecular mechanisms for presumed nsPEF-associated 
host immune responses will make clinical trials more attractive for 
physicians and patients and appealing to investors.
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